Document 2952
 DOCN  M94A2952
 TI    Experience of two years in therapy of AIDS hypersecretory diarrhea with
       octreotide.
 DT    9412
 AU    Miranda-Ruiz R; Feregrino-Goyos M; Alvarado Diez R; Castanon GJ;
       Gallegos-Perez H; Eid-Lidt G; Hospital Especialidades del Centro Medico
       siglo XXI del IMSS,; Mexico D.F., Mexico.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):187 (abstract no. PB0177). Unique
       Identifier : AIDSLINE ICA10/94369623
 AB    OBJECTIVES: Evaluation of the use of octreotide(analog to long range
       action synthetic somatostatin) in therapy of severe and chronic
       hypersecretory diarrhea from AIDS (with more than 10 daily evacuations
       and 2 to 7 liters of daily volume of feces)compared to a similar control
       group. METHODS: 90 HIV patients were studied.Group I of 20 patients
       received conventional antibiotics therapy against opportunistcs germs
       and nutritional support, compared to 70 patients of the Group II that
       received additionally 200 mcg sc of OCTREOTIDE, every 6 hrs, during a
       minimum period of one month. Ten patients received octreotide
       intermitently until 15 months. Age, CD4, weight previous loss, volume
       and number of evacuations,coprocultures, sprecial coproparasitoscopics
       and rectal byopsies were evaluated.Response of the diarrhea and
       microbiological and nutritional response were also evaluated.
       Statistical analysis with chi 2 andT Students. RESULTS: Ages were 32
       aqnd 35 (pNS). CD4 were 54 and 48 (pNS), previous weight loss 18.4% and
       19.2% (pNS); with found microorganisms in both groups:Cryptosporidium,
       cytomegsalovirus, isospora belli, E.histolytica, Giardia lamblia,
       candida, salmonella ascaris and others.Diarrhea severity was similar in
       both groups. After one month of treatment, diarrhea was under control in
       20% of Group I and 70% of Group II (p < 0.01).Increase of body weight
       was observed only in Group II with Medium of 6% in a month(p < 0.02). No
       side effects were observed withthe use of octreotide during long
       treatment periods. 20% of the patients showed recurrence of diarrhea
       after suspension of octreotide's treatment and we have to rebegining
       octreotide intermitently. 20 to 30% of the patients never responded to
       octreotide treatment. The exclusion of cryptosporidium could only be
       diminished in group II. CONCLUSIONS: Octreotide can control up to 70% of
       hypersecretory diarrhea of AIDS.
 DE    Acquired Immunodeficiency Syndrome/*DRUG THERAPY  Adult
       Antibiotics/THERAPEUTIC USE  AIDS-Related Opportunistic Infections/DRUG
       THERAPY  Combined Modality Therapy  Comparative Study  Diarrhea/*DRUG
       THERAPY  Female  Human  Male  Octreotide/*THERAPEUTIC USE  MEETING
       ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).